Effective at the market close on Thursday, September 16, TBIO will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On August 3, 2021, Translate Bio agreed to be acquired by Sanofi for $38.00 per share in cash.
